1. RTS,SA/S01 malaria vaccine had significantly higher efficacy rates compared to placebo within the first year of administration.
2. Over the course of seven years, RTS,SA/S01 malaria vaccine efficacy rates waned significantly.
Evidence Rating Level: 1 (Excellent)
Study Rundown: Malaria continues to be a significant public health concern, with over an estimated...
1. In this phase 3, randomized controlled trial, the candidate vaccine RTS,S/AS01 with or without a booster dose prevented a substantial number of clinical malaria cases in infants and children over a 3-4 year period, with increased vaccine efficacy and prolonged effect with the addition of a booster dose.
1. Efficacy of the RTS,S/AS01E vaccine wanes over four years.
2. The decline in efficacy is greater in areas of higher malaria exposure.
The RTS,S/AS01E is currently the most developed malaria vaccine, with its phase 3 trial slated to end in December 2014. Results continue to show that the vaccine...